HC Wainwright & Co. Reiterates Buy on Artelo Biosciences, Maintains $5 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Artelo Biosciences with a Buy and maintains $5 price target.
Artelo Biosciences: Strong Buy Rating on Clinical Advancement and Solid Financials
Artelo Biosciences: A Strong Buy on Robust Pipeline and Financial Health
10-Q: Quarterly report
Artelo Biosciences Q1 EPS $(0.78) Beats $(1.05) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 2.63 percent decrease over losses of $(
Artelo Biosciences 1Q Loss/Shr 78c >ARTL
Artelo Biosciences 1Q Loss/Shr 78c >ARTL
Press Release: Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinica
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.
Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Artelo Biosciences, Maintains $5 Price Target
HC Wainwright & Co. analyst Vernon Bernardino maintains Artelo Biosciences with a Buy and maintains $5 price target.
Artelo Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 233.33% HC Wainwright & Co. $5 → $5 Maintains Buy 11/14/2023 233.33% HC Wainwright & Co. → $5 R
Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential
Artelo Biosciences Earlier Reported Q4 EPS $(0.99) Misses $(0.56) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.56) by 76.79 percent. This is a 16.1 percent increase over losses of
Recap: Artelo Biosciences Q4 Earnings
Artelo Biosciences (NASDAQ:ARTL) reported its Q4 earnings results on Monday, March 25, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsArtelo Biosciences missed esti
Artelo Biosciences GAAP EPS of -$3.14 Misses by $0.58
Artelo Biosciences FY23 Loss/Shr $3.14 >ARTL
Artelo Biosciences FY23 Loss/Shr $3.14 >ARTL
Press Release: Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update Major achievements in 2023 lay the foundation for key upcoming milestones SOLANA BEACH, Calif., March 2
Artelo Biosciences Has Been Granted European Patent Number EP3723752 Titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)"
Artelo Biosciences Has Been Granted European Patent Number EP3723752 Titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)"
No Data